U.S. Beverage Stock News

NYSE:BRBR
NYSE:BRBRPersonal Products

A Look At BellRing Brands’ (BRBR) Valuation As Class Action Lawsuits Challenge Its Reported Growth Narrative

Several securities law firms have launched class action lawsuits against BellRing Brands (BRBR), accusing the company of misleading investors about what was driving its sales growth and how long that growth could last. See our latest analysis for BellRing Brands. Recent class action headlines are arriving after a sharp reset in expectations, with a 90 day share price return of 48.66% decline and a 1 year total shareholder return of 75.06% decline indicating that momentum has faded over both...
NYSE:LOMA
NYSE:LOMABasic Materials

Does Weaker 2025 Results And ESG Progress Change The Bull Case For Loma Negra (LOMA)?

Loma Negra Compañía Industrial Argentina Sociedad Anónima has released its fourth quarter and full-year 2025 results, reporting AR$225,233 million in Q4 sales and AR$6,245 million in net income, with full-year sales of AR$848,087 million and net income of AR$23,585 million, all lower than the prior year. Amid softer cement volumes, pressure on margins, and a steep drop in earnings per share, Loma Negra still pointed to a stronger concrete segment and ESG progress, including reduced CO₂...
NYSE:COF
NYSE:COFConsumer Finance

Is Capital One’s 360 Savings Settlement Reshaping the Investment Case For Capital One Financial (COF)?

In early March 2026, Capital One Financial agreed to a proposed class action settlement over its 360 Savings accounts, including a US$425.00 million Settlement Fund and a commitment to align future 360 Savings interest rates with its 360 Performance Savings product, subject to court approval. The case highlights how differences in interest paid on similar-looking products and alleged disclosure gaps can create substantial legal, financial, and reputational repercussions for a large consumer...
NasdaqGS:SHC
NasdaqGS:SHCLife Sciences

Why Sotera Health (SHC) Is Down 8.5% After a $382 Million Share Sale And What's Next

Sotera Health recently completed a follow-on equity offering of US$381.75 million, issuing 25,000,000 common shares at US$15.27 each, boosting its capital base but increasing its share count. This fresh equity capital gives Sotera Health more financial flexibility to fund growth projects or reduce debt, while shareholders weigh the impact of dilution. Next, we'll examine how this sizeable equity raise and resulting dilution could reshape Sotera Health's investment narrative going...
NYSE:MRSH
NYSE:MRSHInsurance

Is Marsh & McLennan (MRSH) Blurring The Line Between Consulting And Risk To Sharpen Its Edge?

In March 2026, Marsh announced that Nick Studer will become President and CEO of Marsh Risk on April 1, 2026, succeeding Martin South, who moves into an enterprise-wide role as Chief Client Officer while both remain on the Executive Committee reporting to John Doyle. This leadership reshuffle strengthens Marsh’s focus on client impact and innovation, bringing Oliver Wyman’s consulting expertise closer to the core risk business while a new Oliver Wyman CEO is named. Next, we’ll examine how...
NasdaqGS:MAT
NasdaqGS:MATLeisure

Does Barbie x CCM Shift Mattel’s (MAT) Brand From Toys To Broader Lifestyle Platform?

In recent weeks, CCM Hockey and Mattel announced the launch of an all-new Barbie x CCM Collection of performance hockey gear and apparel aimed at making the sport more inclusive and expressive for a new generation of girls and athletes. This collaboration highlights Mattel’s broader push to extend the Barbie brand beyond traditional toys into sports and lifestyle, aligning with its ambition to build a wider entertainment and consumer-products platform. We’ll now look at how this inclusive...
NasdaqGS:SFNC
NasdaqGS:SFNCBanks

Simmons First Earnings Beat Sparks Questions On Value And Dividend Support

Simmons First National (NasdaqGS:SFNC) reported quarterly results that exceeded revenue and EPS expectations. The bank highlighted resilient operations and solid performance within its regional banking footprint. The update adds fresh information on the company’s current business momentum that has not been reflected in recent coverage. Simmons First National, trading at $18.61, has delivered a quarter that came in ahead of both revenue and earnings forecasts, which puts a fresh spotlight on...
NasdaqGS:WOOF
NasdaqGS:WOOFSpecialty Retail

Is It Time To Reconsider Petco Health and Wellness Company (WOOF) After The Recent Share Price Surge

This article examines whether Petco Health and Wellness Company, at around US$3.62, may represent a bargain or a value trap by exploring what the current share price might indicate about the business. The stock has recently experienced sharp moves, with returns of 52.1% over the last 7 days, 44.2% over the last 30 days, 27.0% year to date and 51.5% over the last year. However, the 3 year and 5 year returns show declines of 63.1% and 84.4%, which tells a very different story. These swings...
NYSE:ORI
NYSE:ORIInsurance

Old Republic Leadership Shift And Valuation Gap As Wordekemper Takes Helm

Old Republic International (NYSE:ORI) has appointed Doug Wordekemper as CEO of Old Republic Professional. The move is part of a broader organizational leadership change within the Professional division. The appointment brings a leader with extensive industry experience into a key role overseeing the Professional business. Old Republic International, through its Professional division, focuses on specialty insurance solutions for professional liability and related risks. Leadership changes in...
NasdaqCM:KARO
NasdaqCM:KAROSoftware

Karooooo (NasdaqCM:KARO) Valuation Check As Cartrack Crosses Two Million Subscriber Milestone

Subscriber milestone puts Karooooo (KARO) in focus Cartrack, a subsidiary of Karooooo (KARO), has surpassed two million active subscribers in South Africa. This milestone puts the group’s mobility SaaS model and customer-focused execution firmly on investors’ radar. See our latest analysis for Karooooo. Karooooo’s latest subscriber milestone lands after a period where the share price has moved steadily rather than sharply, with a 5.69% year to date share price return and a 19.93% one year...
NYSE:WEX
NYSE:WEXDiversified Financial

Is WEX (WEX) Offering Value After Recent Share Price Volatility And Mixed Valuation Signals

If you are wondering whether WEX at around US$159.95 is priced fairly or offering value, you are not alone. This article is built to help you assess that question using several valuation tools. The stock has been relatively mixed recently, with a 7.8% return year to date and 3.8% over the last year, alongside a 4.3% decline over the past week and a 1.4% gain over the last 30 days. These movements can change how the market is thinking about its risk and opportunity. Recent coverage has...
NYSE:USPH
NYSE:USPHHealthcare

A Look At U.S. Physical Therapy’s Valuation As Shares Pull Back And P/E Stands At 53.9x

Setting the scene on U.S. Physical Therapy With no fresh headline event driving U.S. Physical Therapy (USPH) today, investors are left weighing a share price of $76.83 alongside recent return figures and the company’s latest reported revenue and net income. See our latest analysis for U.S. Physical Therapy. The recent share price pullback, including a 1-day share price return of 1.35% decline and a 30-day share price return of 11.63% decline, sits alongside a 1-year total shareholder return...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA Filings - Has The Bull Case Changed?

In recent months, Driehaus Capital Management and Deerfield Management Company have sharply increased their holdings in Praxis Precision Medicines, adding hundreds of thousands of shares and committing a combined investment of more than US$346.79 million as the company filed two FDA new drug applications for ulixacaltamide and relutrigine. This combination of larger institutional ownership, advancing late‑stage neuroscience candidates and a cash position supported by roughly US$1.55 billion...
NYSE:CLVT
NYSE:CLVTProfessional Services

Is Clarivate (CLVT) Using Claude Integration to Deepen Its Data Moat or Just Follow Hype?

In early March 2026, Clarivate Plc announced it had integrated its Cortellis Regulatory Intelligence data with Anthropic’s Claude via the open Model Context Protocol, giving biopharma, biotech, medtech and clinical research organizations context-aware access to authoritative regulatory data directly within their existing AI workflows. This move highlights how Clarivate is aiming to embed its validated regulatory content deeper into customers’ day-to-day decision processes, potentially...
NasdaqGS:SVCO
NasdaqGS:SVCOSoftware

Is Silvaco Group’s (SVCO) New MIPI IP Rollout Enough To Reframe Its Loss-Making Profile?

In March 2026, Silvaco Group, Inc. completed a follow-on at-the-market US$15 million common stock offering and reported full-year 2025 revenue of US$63.06 million with a net loss of US$41.21 million, alongside guidance for first-quarter 2026 revenue of US$15 million to US$19 million. A few days earlier, the company also announced the immediate availability of Mixel MIPI Production Ready Offerings, broadening its silicon-proven mixed-signal interface IP portfolio across advanced process nodes...
NasdaqGM:EH
NasdaqGM:EHAerospace & Defense

Did EHang’s Q4 Profit Amid Full-Year Losses Just Shift EHang Holdings’ (EH) Investment Narrative?

EHang Holdings Limited reported its fourth-quarter 2025 results on March 12, 2026, with sales rising to CNY 243.78 million and quarterly net income reaching CNY 10.49 million, while full-year 2025 revenue increased to CNY 509.50 million alongside a full-year net loss of CNY 230.54 million. The shift from a quarterly net loss in the prior year to profitability in Q4 2025, even as the full year remained loss-making, highlights a meaningful improvement in operating performance and cost...
NYSE:EVR
NYSE:EVRCapital Markets

Assessing Evercore (EVR) Valuation After Recent Share Price Pullback

Why Evercore (EVR) is on investors’ radar today Evercore (EVR) has drawn fresh attention after a period of mixed share performance, with a recent 0.4% daily gain that contrasts with weaker moves over the past week, month, and past 3 months. See our latest analysis for Evercore. That 0.4% 1 day share price gain comes after a tougher spell, with a 7.2% 7 day share price decline and a 23.6% year to date share price decline, even though the 1 year total shareholder return is 35.1% and the 3 year...
NasdaqGS:WYNN
NasdaqGS:WYNNHospitality

Did Wynn’s (WYNN) Al Marjan Construction Restart Quietly Redefine Its Middle East Expansion Narrative?

Wynn Resorts has resumed construction on its US$5.10 billion Wynn Al Marjan Island integrated resort in Ras Al Khaimah, UAE, after a brief security-related pause, while maintaining close coordination with US and UAE authorities to safeguard employees and operations. This restart reinforces Wynn’s push into the Middle East through a 40% stake in the project, marking the region’s first large-scale casino resort and expanding its luxury hospitality footprint beyond existing US and Asia...
NYSE:ENVA
NYSE:ENVAConsumer Finance

Is Enova International (ENVA) Still Attractively Priced After Recent Share Price Pullback?

If you are wondering whether Enova International at around US$134.11 is still offering value or already pricing in a lot of optimism, you are asking the right question for this stock. The share price has seen a 2.5% decline over the last 7 days and a 10.1% decline over the last 30 days, although the 1 year return sits at 44.8% and the 3 year return is 220.5%, with 5 year returns at 266.4%. Recent coverage of Enova International has focused on its position within the diversified financials...
NasdaqGS:SGRY
NasdaqGS:SGRYHealthcare

Surgery Partners (SGRY) Is Down 7.3% After Soft 2026 Outlook, Buyback Launch, and New Director

Earlier this month, Surgery Partners, Inc. reported 2025 results showing higher sales of US$885.0 million for the fourth quarter and US$3.31 billion for the year but continuing net losses, issued softer 2026 revenue guidance of US$3.35 billion to US$3.45 billion, launched a new US$200.0 million share repurchase program, and appointed veteran health system executive Lloyd Dean as an independent director. These developments, alongside pressure from activist investor Ortelius Advisors pushing...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Swings

Corvus Pharmaceuticals stock moves after recent performance swings Corvus Pharmaceuticals (CRVS) has been drawing fresh attention as its share price reflected sharp recent moves, including a 4.3% decline over the past day and a month return that is roughly 17.9% lower. See our latest analysis for Corvus Pharmaceuticals. Even with the latest 4.3% one day share price decline and a softer 30 day share price return of 17.9%, Corvus Pharmaceuticals still shows strong upward momentum, with a 90 day...
NasdaqGM:WINA
NasdaqGM:WINASpecialty Retail

Winmark’s Caviar Cruise Nod: Does Exceptional ROIC Redefine Its Quality Narrative for WINA?

Winmark Corp recently passed the Caviar Cruise quality investing screen, which highlights companies with durable competitive strengths, high profitability, and solid financial health. This recognition emphasizes Winmark’s franchise-based model, where high returns on invested capital and strong cash flow conversion underpin its operational quality. We’ll now examine how Winmark’s very high return on invested capital shapes the company’s investment narrative following these quality-focused...
NasdaqGS:VRSK
NasdaqGS:VRSKProfessional Services

A Look At Verisk Analytics (VRSK) Valuation After New Accelerated Share Repurchase Program

Why Verisk’s new buyback is drawing fresh attention Verisk Analytics (VRSK) has come back into focus after launching a $1.5b accelerated share repurchase program and stepping up investor outreach through an Analyst and Investor Day plus back to back conference appearances. See our latest analysis for Verisk Analytics. The 1 month share price return of 11.04% and 1 day move of 1.61% to US$201.22 sit against a 1 year total shareholder return of 29.73% decline. The recent buyback announcement...
NasdaqGM:AMAL
NasdaqGM:AMALBanks

A Look At Amalgamated Financial (AMAL) Valuation After Earnings Beat And Continued Insider Selling

Amalgamated Financial (AMAL) is back in focus after reporting fourth quarter 2025 earnings, with revenue of $87.91 million that topped forecasts, alongside continued insider share sales by a senior executive. See our latest analysis for Amalgamated Financial. The latest quarterly update and ongoing insider selling come against a mixed price backdrop, with a 1 day share price return of 0.37% and a 30 day share price decline of 7.95%, while the 90 day share price return of 18.10% and 1 year...